Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Capricor Therapeutics (CAPR) Accumulated Depreciation & Amortization (2018 - 2025)

Capricor Therapeutics has reported Accumulated Depreciation & Amortization over the past 12 years, most recently at $5.2 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $5.2 million for Q4 2025, up 49.29% from a year ago — trailing twelve months through Dec 2025 was $5.2 million (up 49.29% YoY), and the annual figure for FY2025 was $5.2 million, up 49.29%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $5.2 million at Capricor Therapeutics, up from $4.6 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CAPR hit a ceiling of $5.2 million in Q4 2025 and a floor of $756712.0 in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $1.8 million (2023), compared with a mean of $2.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 5.31% in 2021 and later surged 86.7% in 2023.
  • Capricor Therapeutics' Accumulated Depreciation & Amortization stood at $756712.0 in 2021, then surged by 56.15% to $1.2 million in 2022, then surged by 86.7% to $2.2 million in 2023, then skyrocketed by 56.39% to $3.5 million in 2024, then surged by 49.29% to $5.2 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $5.2 million (Q4 2025), $4.6 million (Q3 2025), and $4.2 million (Q2 2025) per Business Quant data.